These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17661640)

  • 21. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
    Lismond A; Carbonnelle S; Verhaegen J; Schatt P; De Bel A; Jordens P; Jacobs F; Dediste A; Verschuren F; Huang TD; Tulkens PM; Glupczynski Y; Van Bambeke F
    Int J Antimicrob Agents; 2012 Mar; 39(3):208-16. PubMed ID: 22245497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
    Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
    Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W; Assawasanti K; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus pneumoniae.
    Seok H; Kang CI; Huh K; Cho SY; Ha YE; Chung DR; Peck KR
    Microb Drug Resist; 2018 Nov; 24(9):1412-1416. PubMed ID: 29565225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic strategy in severe community-acquired pneumococcal pneumonia.
    Le Bris-Tomczak A; Bedos JP; Billon C; Samdjee F; Le Monnier A
    Med Mal Infect; 2012 May; 42(5):226-34. PubMed ID: 22583782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumonia due to resistant Streptococcus pneumoniae.
    Täuber MG
    Schweiz Med Wochenschr; 2000 Dec; 130(49):1873-9. PubMed ID: 11153392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decrease in drug resistance in pneumococcal community-acquired pneumonia.
    Obando I; Arroyo L; Sanchez-Tatay D
    Chest; 2007 Jul; 132(1):359; author reply 359-60. PubMed ID: 17625101
    [No Abstract]   [Full Text] [Related]  

  • 28. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia.
    Lismond A; Carbonnelle S; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2011 Apr; 66(4):948-51. PubMed ID: 21393137
    [No Abstract]   [Full Text] [Related]  

  • 30. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities.
    Klugman KP; Low DE; Metlay J; Pechere JC; Weiss K
    Int J Antimicrob Agents; 2004 Nov; 24(5):411-22. PubMed ID: 15519470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Community-acquired pneumonia in HIV-infected children: a global perspective.
    Gray DM; Zar HJ
    Curr Opin Pulm Med; 2010 May; 16(3):208-16. PubMed ID: 20375782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.
    File TM
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():31-41. PubMed ID: 16669927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004).
    Draghi DC; Jones ME; Sahm DF; Tillotson GS
    Int J Antimicrob Agents; 2006 Dec; 28(6):525-31. PubMed ID: 17101260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S; Erdem H; Pahsa A
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
    Low DE
    Infect Dis Clin North Am; 2013 Mar; 27(1):87-97. PubMed ID: 23398867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of lower respiratory tract infections in immunocompetent adults (community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease): the challenge of a new consensus conference].
    Chidiac C
    Med Mal Infect; 2006 Jan; 36(1):1-3. PubMed ID: 16413722
    [No Abstract]   [Full Text] [Related]  

  • 38. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2005 Dec; 26(6):575-616. PubMed ID: 16388429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia.
    Metlay JP; Hofmann J; Cetron MS; Fine MJ; Farley MM; Whitney C; Breiman RF
    Clin Infect Dis; 2000 Mar; 30(3):520-8. PubMed ID: 10722438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).
    Hawser SP
    J Infect; 2010 Apr; 60(4):306-8. PubMed ID: 20144899
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.